Benzinga - by Benzinga Neuro, Benzinga Staff Writer.
Oracle’s recent stock price decline presents an appealing buying opportunity, according to Evercore analysts, who upgraded their rating on the cloud service provider’s shares on Monday.
Barron’s reported that Evercore’s Kirk Materne and his team have shifted their rating on Oracle (NYSE:ORCL) stock from ‘In Line’ to ‘Outperform’. The team also increased their price target from $131 to $135, suggesting a 23% upside from Friday’s closing price of $109.96.
Oracle’s stock has dropped 13% since Sep. 11, following the company’s Q1 results, which didn’t meet Wall Street’s expectations. The company's recently acquired Cerner healthcare software business is encountering challenges as customers transition from upfront payments to cloud subscriptions, Oracle CEO Safra Catz alerted investors.
However, Evercore analysts believe the post-results pullback offers a more attractive entry point for investors.
Despite short-term debates around Cerner, Materne noted the "apps and infrastructure cloud businesses are now big enough as a percentage of revenue to drive total revenue growth in the high single digits going forward."
Evercore expects Oracle's core cloud offering to account for approximately half of total revenue by fiscal 2026, boosting revenue to $62.9 billion from $40.5 billion in 2021. This is slightly below management’s forecast of $65 billion in revenue for fiscal 2026.
Read Next: Dogecoin Co-Creator, Elon Musk Blast SEC For Denying Inherent Value Of Cryptos: ‘Return All The Taxes…You Horrific Evil Hypocrites’
Image via Shutterstock
Engineered by
Benzinga Neuro, Edited by
Pooja Rajkumari
The GPT-4-based Benzinga Neuro content generation system exploits the
extensive Benzinga Ecosystem, including native data, APIs, and more to
create comprehensive and timely stories for you.
Learn more.
Latest Ratings for ORCL
| Mar 2022 | B of A Securities | Maintains | Neutral | |
| Mar 2022 | BMO Capital | Maintains | Market Perform | |
| Mar 2022 | Piper Sandler | Downgrades | Neutral | Underweight |
View the Latest Analyst Ratings
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.